atorvastatin has been researched along with Pneumonia in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Bašić-Jukić, N; Sabljić, Z | 1 |
| Buendía, JA; Justinico Castro, JA; Sánchez Villamil, JP; Sinisterra, D; Vela, LJT; Zuluaga Salazar, AF | 1 |
| Alqahtani, S; Du, X; Ferreira, C; Franco, J; Kobos, LM; Shannahan, JH; Xia, L | 1 |
| Amniattalab, A; Hobbenaghi, R; Khoramjouy, M; Malekinejad, H | 1 |
| Chang, YH; Chien, LN; Chuang, MT; Lin, CF; Liu, JC | 1 |
| Foulet-Rogé, A; Gagnadoux, F; Goupil, F; Kernaonet, E; Lebas, FX; Molinier, O; Paris, A | 1 |
6 other study(ies) available for atorvastatin and Pneumonia
| Article | Year |
|---|---|
Toxic myopathy and liver damage caused by concomitant therapy with remdesivir, atorvastatin, ezetimibe, and tacrolimus in a renal transplant patient with recently treated SARS-CoV-2 induced pneumonia: A case report.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Atorvastatin; COVID-19 Drug Treatment; Ezetimibe; Humans; Kidney Transplantation; Liver; Myotoxicity; Pneumonia; SARS-CoV-2; Tacrolimus | 2022 |
Comparison of four pharmacological strategies aimed to prevent the lung inflammation and paraquat-induced alveolar damage.
Topics: Animals; Antioxidants; Ascorbic Acid; Atorvastatin; Cyclophosphamide; Dexamethasone; Drug Therapy; Drug Therapy, Combination; Heparin; Heparin, Low-Molecular-Weight; Lung; Paraquat; Pneumonia; Pulmonary Alveoli; Pulmonary Fibrosis; Rats, Wistar; Treatment Outcome | 2019 |
Exacerbation of Nanoparticle-Induced Acute Pulmonary Inflammation in a Mouse Model of Metabolic Syndrome.
Topics: Animals; Atorvastatin; Diet, High-Fat; Diet, Western; Disease Models, Animal; Disease Susceptibility; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Metabolic Syndrome; Metal Nanoparticles; Mice; Mice, Inbred C57BL; Pneumonia; Real-Time Polymerase Chain Reaction; RNA, Messenger; Silver; Treatment Outcome | 2020 |
Atorvastatin attenuates the paraquat-induced pulmonary inflammation via PPARγ receptors: a new indication for atorvastatin.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Heptanoic Acids; Herbicides; Interleukin-6; Lung; Male; Malondialdehyde; Nitric Oxide; Paraquat; Peroxidase; Pioglitazone; Pneumonia; PPAR gamma; Pyrroles; Rats, Wistar; Thiazolidinediones; Tumor Necrosis Factor-alpha; Weight Loss | 2014 |
Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: a nested case-control study.
Topics: Aged; Atorvastatin; Case-Control Studies; Comorbidity; Diabetes Mellitus; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart Failure; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Indoles; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Pneumonia; Protective Factors; Retrospective Studies; Risk Factors; Simvastatin; Stroke; Taiwan | 2016 |
[Drug-induced pneumonitis due to sirolimus: an interaction with atorvastatin?].
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Interactions; Female; Heptanoic Acids; Humans; Immunosuppressive Agents; Male; Middle Aged; Pneumonia; Pyrroles; Sirolimus | 2012 |